In addition, PSMA has been widely explored as a biomarker of prostate cancer activity for disease imaging, using radioactive PSMA tracers [98,99], and as a disease-specific target in the field of PSMA theranostics [100,101]. Here, FOLH1 is linked to prostate carcinoma.